Back to mobile site

William Blair: 'view BridgeBio as becoming a core smidcap biotech holding'

October 6, 2026 10:46 AM EDT Send to a Friend
William Blair analyst John Boyle reiterated an Outperform rating on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "For BridgeBio, while the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login